VVelarionINTELLIGENCE
Sign inStart free trial
Start free trial
Biopharma & Life Sciences

Tvardi Therapeutics, Inc. Executive Compensation (FY25)

CARA · Executive and director compensation, fiscal 2023 to 2025
Chief executive, fiscal 2025
◇
Imran Alibhai
Median of the other named officers
$1,139,451
5 officers, excluding the chief executive
Latest say-on-pay support
=
June 9, 2026
Free for 3 days · no card

See how Tvardi Therapeutics, Inc.’s pay stands against its peers

  • Tvardi Therapeutics, Inc.'s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on CARASee the plan and pricing
No card. Nothing is charged, and the trial ends on its own. After the trial: $499/month, or $5,000/year, about two months free.
Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
140 figures on this page: 134 cited to the filing that reported them, 6 calculated from figures it prints. See the citations
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Imran Alibhai: $857,330 → $3,116,090 (263.5% higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Tvardi Therapeutics, Inc.'s chief executive and what were they paid?
Imran Alibhai, Chief Executive Officer and Director, received $3,116,090 in total compensation for fiscal 2025. Alibhai's total moved 263.5% higher from the $857,330 reported for fiscal 2024.
What was Tvardi Therapeutics, Inc.'s say-on-pay result?
The say-on-pay proposal drew 95.1% of votes cast including abstentions in favor at the meeting held June 9, 2026 for fiscal 2025.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Christopher Posner
President and Chief Executive Officer
◇——◇◇—◇◇
Joana Goncalves
former Chief Medical Officer
Departed during or after this year
◇——◇◇—◇◇
Ryan Maynard
Chief Financial Officer
◇——◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Christopher Posner
Former (Cara) President and Chief Executive Officer
◇——◇——◇◇
Imran Alibhai
Chief Executive Officer and Director
◇◇————◇◇
Ryan Maynard
Former (Cara) Chief Financial Officer
◇——◇——◇— not reconciled
Scott Terrillion
Former (Cara) General Counsel, Secretary and Chief Compliance Officer
◇——◇——◇◇
John Kauh
Chief Medical Officer
◇◇—————— not reconciled
Dan Conn
Chief Financial Officer
◇◇—————◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Imran Alibhai
Chief Executive Officer and Director
◇——◇◇—◇◇
Christopher Posner
Former (Cara) President and Chief Executive Officer
Departed during or after this year
◇—————◇◇
John Kauh
Chief Medical Officer
◇——◇◇—◇◇
Dan Conn
Chief Financial Officer
◇——◇◇——◇
Ryan Maynard
Former (Cara) Chief Financial Officer
Departed during or after this year
◇—————◇◇
Scott Terrillion
Former (Cara) General Counsel, Secretary and Chief Compliance Officer
Departed during or after this year
◇—————◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
John KauhOption◇—◇December 16, 2035
Option◇—◇April 17, 2035
Option◇—◇January 12, 2033
Imran AlibhaiOption——◇December 16, 2031
Option——◇January 30, 2031
Option——◇January 16, 2029
Option◇—◇December 16, 2035
Option◇—◇April 17, 2035
Dan ConnOption◇—◇December 16, 2035
Option◇—◇April 17, 2035
Option◇—◇February 4, 2032
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Susan Shiff, Ph.D
◇—◇——◇◇
Martin Vogelbaum
◇————◇◇
Sujal Shah
◇—◇———◇
Michael S. Wyzga
◇—◇———◇
Shaheen Wirk, M.D
◇—◇———◇
Wallace L. Hall Jr
◇—◇———◇
Cynthia Smith
◇—◇———◇
Jeffrey L. Ives, Ph.D
◇————◇◇
Helen M. Boudreau
◇————◇◇
Lisa von Moltke
◇————◇◇
Imran Alibhai, Ph.D served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Lead independent director premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025June 9, 2026=◇◇◇
2023June 4, 2024=◇◇◇
2022June 1, 2023=◇◇◇
2021June 2, 2022=◇◇◇
2020June 3, 2021=◇◇◇
2019June 4, 2020=◇◇◇
Tell me when Tvardi Therapeutics, Inc. files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Tvardi Therapeutics, Inc. disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Tvardi Therapeutics, Inc.'s disclosed peer group is defensible, who names Tvardi Therapeutics, Inc. back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
140 figures on this page: 134 cited to the filing that reported them, 6 calculated from figures it prints.
134 cited to the filing
6 calculated from the filing

Documents cited

  1. 0001104659-26-072930
    Proposal 2 – Non-Binding, Advisory Vote on Executive Compensation The stockholders approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers, by the followi
  2. 0001104659-26-047695
    Director Compensation · Outstanding Equity Awards at 2025 Fiscal-Year End · Summary Compensation Table
  3. 0001104659-24-069625
    Proposal 2 - Approval, on a Non-Binding Advisory Basis, of the Compensation of the Company’s Named Executive Officers The stockholders approved, on a non-binding advisory basis, the compensation of th
  4. 0001104659-23-067541
    Proposal 2 – Approval, on a Non-Binding Advisory Basis, of the Compensation of the Company’s Named Executive Officers The stockholders approved, on a non-binding advisory basis, the compensation of th
  5. 0001104659-22-069040
    Proposal 2 – Approval, on a Non-Binding Advisory Basis, of the Compensation of the Company’s Named Executive Officers The stockholders approved, on a non-binding advisory basis, the compensation of th
  6. 0001104659-21-077712
    Proposal 2 – Approval, on a Non-Binding Advisory Basis, of the Compensation of the Company’s Named Executive Officers The stockholders approved, on a non-binding advisory basis, the compensation of th
  7. 0001104659-20-070389
    Proposal 2 – Approval, on a Non-Binding Advisory Basis, of the Compensation of the Company’s Named Executive Officers The stockholders approved, on a non-binding advisory basis, the compensation of th
  8. 0001104659-24-049971
    2023 Summary Compensation Table
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Tvardi Therapeutics, Inc. executive compensation, FY2023–FY2025.” https://intel.velarion.ai/comp/CARA (accessed 2026).
Short form: data: Velarion
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Tvardi Therapeutics, Inc. and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.

Biopharma & Life Sciences rankings

Terms on this page

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}